GSK plc reported positive results from its phase III trials of bepirovirsen for chronic hepatitis B on January 7, 2026, showing significant functional cure rates in over 1,800 patients. Bepirovirsen could become a first-in-class treatment, aimed at benefiting over 250 million worldwide affected by the disease.